(Q45911764)

17 December 2017

title

Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. (English)

1 reference

17 December 2017

1 reference

iron deficiency anemia

1 reference

Myles Wolf

1

1 reference

17 December 2017

Todd A Koch

series ordinal

2

1 reference

17 December 2017

David B Bregman

series ordinal

3

1 reference

17 December 2017

publication date

1 August 2013

1 reference

17 December 2017

Journal of Bone and Mineral Research

published in

1 reference

17 December 2017

volume

28

1 reference

17 December 2017

issue

8

1 reference

17 December 2017

page(s)

1793-1803

1 reference

17 December 2017

Ferric carboxymaltose: a review of its use in iron-deficiency anaemia

cites work

1 reference

Safety and Efficacy of Intravenous Ferric Carboxymaltose (750 mg) in the Treatment of Iron Deficiency Anemia: Two Randomized, Controlled Trials

21 January 2018

1 reference

Comparative efficacy and safety of intravenous ferric carboxymaltose in the treatment of postpartum iron deficiency anemia

21 January 2018

1 reference

FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease.

21 January 2018

1 reference

A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial

21 January 2018

1 reference

A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients

21 January 2018

1 reference

Ferric carboxymaltose injection in the treatment of postpartum iron deficiency anemia: a randomized controlled clinical trial

21 January 2018

1 reference

Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial

21 January 2018

1 reference

Saccharated ferric oxide-induced osteomalacia in Japan: iron-induced osteopathy due to nephropathy

21 January 2018

1 reference

Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers

21 January 2018

1 reference

Severe Hypophosphatemia After Intravenous Administration of Iron Carboxymaltose in a Stable Renal Transplant Recipient

21 January 2018

1 reference

FGF-23: More than a regulator of renal phosphate handling?

21 January 2018

1 reference

FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: a prospective study

21 January 2018

1 reference

Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice.

21 January 2018

1 reference

Iron modifies plasma FGF23 differently in autosomal dominant hypophosphatemic rickets and healthy humans

21 January 2018

1 reference

Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis

21 January 2018

1 reference

Fibroblast growth factor 23: state of the field and future directions

21 January 2018

1 reference

Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/JBMR.1923

1 reference

17 December 2017

1 reference

17 December 2017